Ventyx Biosciences Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $1.99 billion
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Ventyx Biosciences Inc had its IPO on 2021-10-21 under the ticker symbol VTYX.
The company operates in the Healthcare sector and Biotechnology industry. Ventyx Biosciences Inc has a staff strength of 91 employees.
Shares of Ventyx Biosciences Inc opened at $34.02 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $34.02 - $35.2, and closed at $34.62.
This is a +1.61% increase from the previous day's closing price.
A total volume of 359,703 shares were traded at the close of the day’s session.
In the last one week, shares of Ventyx Biosciences Inc have increased by +2.58%.
Ventyx Biosciences Inc's Key Ratios
Ventyx Biosciences Inc has a market cap of $1.99 billion, indicating a price to book ratio of 5.015 and a price to sales ratio of 0.
In the last 12-months Ventyx Biosciences Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-169544992. The EBITDA ratio measures Ventyx Biosciences Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Ventyx Biosciences Inc’s operating margin was 0% while its return on assets stood at -34.72% with a return of equity of -55.3%.
In Q2, Ventyx Biosciences Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Ventyx Biosciences Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-2.86 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Ventyx Biosciences Inc’s profitability.
Ventyx Biosciences Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -16.6876. Its price to sales ratio in the trailing 12-months stood at 0.
Ventyx Biosciences Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $348.76 million
- Total Liabilities
- $20.03 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Ventyx Biosciences Inc ended 2023 with $348.76 million in total assets and $0 in total liabilities. Its intangible assets were valued at $348.76 million while shareholder equity stood at $327.81 million.
Ventyx Biosciences Inc ended 2023 with $0 in deferred long-term liabilities, $20.03 million in other current liabilities, 6000.00 in common stock, $-318407000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $51.72 million and cash and short-term investments were $332.25 million. The company’s total short-term debt was $439,000 while long-term debt stood at $0.
Ventyx Biosciences Inc’s total current assets stands at $346.70 million while long-term investments were $0.00 and short-term investments were $280.54 million. Its net receivables were $0 compared to accounts payable of $4.09 million and inventory worth $0.
In 2023, Ventyx Biosciences Inc's operating cash flow was $0 while its capital expenditure stood at $195000.
Comparatively, Ventyx Biosciences Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Ventyx Biosciences Inc stock is currently trading at $34.62 per share. It touched a 52-week high of $47.251 and a 52-week low of $47.251. Analysts tracking the stock have a 12-month average target price of $56.75.
Its 50-day moving average was $34.38 and 200-day moving average was $35.24 The short ratio stood at 16.96 indicating a short percent outstanding of 0%.
Around 372.2% of the company’s stock are held by insiders while 10244.7% are held by institutions.
Frequently Asked Questions About Ventyx Biosciences Inc
Similar Industry Stocks (Biotechnology)
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. Its lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.